NINDS CREATE Devices: Translational and Early Feasibility Studies on the Path to Pre-Market Approval (PMA) or Humanitarian Device Exemption (HDE) (UH2/UH3)

Sponsor: National Institute of Neurological Disorders and Stroke
Due Date: February 8, 2017
Award: Budgets are not limited but must reflect the actual needs of the project. UH2 phase should rarely exceed $1,000,000 per year; UH3 phase should rarely exceed $1,500,000 per year. Total duration of both UH2 and UH3 may not exceed 5 years.